source
- Agios ends development of tebapivat in low-risk MDS following subpar resultsAgios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…Endpoints · 2mo ago↗ source
- Allogene CEO to step down; Agios drug fails key testDavid Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.BioPharma Dive · 2mo ago↗ source
- Can a chaotic FDA still deliver on faster drug development?As leadership changes create more instability at the FDA, here’s what one former agency official thinks it will take to keep speedier drug approvals on track.